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Abstract The Tail Suspension Test (TST), which mea-
sures behavioral despair, is widely used as an animal model
of human depressive disorders and antidepressant efﬁcacy.
In order to identify novel genes involved in the regulation
of TST performance, we crossed an inbred strain exhibiting
low immobility in the TST (RIIIS/J) with two high-
immobility strains (C57BL/6J and NZB/BlNJ) to create
two distinct F2 hybrid populations. All F2 offspring
(n = 655) were genotyped at high density with a panel of
SNP markers. Whole-genome interval mapping of the F2
populations identiﬁed statistically signiﬁcant quantitative
trait loci (QTLs) on mouse chromosomes (MMU) 4, 6, and
X. Microarray analysis of hippocampal gene expression in
the three parental strains was used to identify potential
candidate genes within the MMUX QTLs identiﬁed in the
NZB/BlNJ 9 RIIIS/J cross. Expression of Gabra3, which
encodes the GABAA receptor a3 subunit, was robust in the
hippocampus of B6 and RIIIS mice but absent from NZB
hippocampal tissue. To verify the role of Gabra3 in regu-
lating TST behavior in vivo, mice were treated with
SB-205384, a positive modulator of the a3 subunit.
SB-205384 signiﬁcantly reduced TST immobility in B6
mice without affecting general activity, but it had no effect
on behavior in NZB mice. This work suggests that
GABRA3 regulates a behavioral endophenotype of
depression and establishes this gene as a viable new target
for the study and treatment of human depression.
Introduction
Major depressive disorder (MDD) has a lifetime prevalence
rate of approximately 20% and accounts for up to 80% of
affective illnesses (Kessler et al. 2003). There is a signiﬁ-
cant genetic component to MDD, as twin and adoption
studies indicate that the disorder has a 40–60% heritability
rate (Sullivan et al. 2000). However, the complex, hetero-
geneous nature of depression has stymied identiﬁcation of
causative genes. To date, gene identiﬁcation has been
based primarily on a candidate gene approach informed by
the hypothesized mode of action of antidepressant drugs on
the monoaminergic system (Peters et al. 2004). However,
the candidate gene approach is hindered by our limited
understanding of the biology of depression: There are
likely to be a number of unknown genes that regulate the
propensity for depression in addition to those directly
targeted by current pharmacological agents.
Genome-wide association studies (GWAS) offer an
unbiased means to identify causative genes, but such studies
generally have been unsuccessful when applied to psychi-
atric disorders (Craddock et al. 2005). A number of the
confounding variables associated with human studies,
including the effects of genetic background and the envi-
ronment,canbeminimizedbyusinganimal models.Several
behavioral tests that approximate discrete endophenotypes
of human depression have been established, including the
Tail Suspension Test (TST) and the Forced Swim Test
(FST) (Cryan and Mombereau 2004; Porsolt et al. 1977). In
both tests, the immobility observed when an animal is faced
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despair. While no animal model can fully recapitulate the
range ofsymptoms associated with depressive disorders, the
relevanceof the TST and FSTtohumandepression hasbeen
extensively documented. First, deletion or overexpression
of genes linked to human depression affects immobility in
the TST and FST (Cryan et al. 2005; Urani et al. 2005).
Second, antidepressant treatment reduces immobility in the
TST and FST, while antipsychotic treatment has no effect
(Crowley et al. 2004). Finally, factors that increase the
susceptibility to depression in humans, such as amphet-
amine withdrawal and chronic social stress, increase
immobility in the TST (Cryan and Mombereau 2004).
Inbred mouse strains differ in their propensity for
behavioral despair (Jacobson and Cryan 2007). As this
effect is highly heritable, the F2 offspring of an intercross
between two strains can be used to map the genetic
determinants of baseline TST behavior. Several groups
have used quantitative trait locus (QTL) mapping to iden-
tify loci believed to regulate variability in TST perfor-
mance (Lad et al. 2007; Liu et al. 2007; Tomida et al. 2009;
Turri et al. 2001; Yoshikawa et al. 2002). However, these
experiments have not generated overlapping loci, and the
results have not been independently replicated. Further-
more, the QTLs generally range from 20 to 40 Mb in size,
making candidate gene identiﬁcation difﬁcult. Indeed, with
the exception of a single study, this method has not resulted
in the identiﬁcation of speciﬁc quantitative trait genes
(Tomida et al. 2009).
We recently completed a survey of baseline behavior in
33 inbred mouse strains and found that TST baseline
immobility ranges from 7 to 60% in a strain-dependent
manner. In the present study, two mapping populations
were created by crossing strains at opposite ends of this
distribution: The low-immobility strain RIIIS/J (R3) was
crossed with either the high-immobility C57BL/6J (B6) or
NZB/BlNJ (NZB) strain. F2 offspring were phenotyped in
the TST and genotyped at approximately 5-Mb intervals.
Interval mapping conducted for each cross separately
identiﬁed a signiﬁcant B6-speciﬁc QTL on MMU6 and a
signiﬁcant NZB-speciﬁc QTL on MMUX. The genotype
data from the two crosses were combined and reanalyzed,
yielding a signiﬁcant QTL on MMU4. The MMU4 and
MMU6 loci are within the conﬁdence intervals of previ-
ously published TST QTLs (Liu et al. 2007; Yoshikawa
et al. 2002). Genome-wide gene expression data from
hippocampal tissue collected from the three parental strains
were used to identify genes within the signiﬁcant loci that
were differentially expressed between strains and were
therefore good candidate quantitative trait genes. One gene
located within the MMUX locus, the GABAA a3 receptor
subunit (Gabra3), was expressed in both R3 and B6
hippocampus but was absent from NZB hippocampus. To
conﬁrm the in vivo signiﬁcance of Gabra3, we measured
TST immobility in B6 and NZB mice treated with a
GABRA3-speciﬁc agonist. Our results indicate that
Gabra3 regulates baseline TST behavior in mice and may
represent a novel therapeutic target for the treatment of
depression.
Materials and methods
Animals
Female and male RIIIS/J, C57BL/6J, and NZB/BlNJ mice
were obtained from The Jackson Laboratory (Bar Harbor,
ME) and maintained on a 12:12-h light:dark cycle. Mice
were allowed to acclimate for at least 1 week prior to
behavioral testing. Following behavioral testing, mating
trios consisting of two R3 females and either a B6 or NZB
male were established in order to produce B6 9 R3 and
NZB 9 R3 F1 offspring. The F1 offspring were paired in
brother–sister matings. A total of 305 B6 9 R3 F2 off-
spring (B6F2: 162 male, 143 female) and 350 NZB 9 R3
F2 offspring (NZBF2: 185 male, 165 female) were phe-
notyped in the TST.
All animal procedures were approved by the Scripps
Florida Animal Care and Use Committee.
Behavioral testing
Parental, F1, and F2 intercross mice were tested for base-
line immobility in the TST as previously described (Miller
et al. 2008). Brieﬂy, mice were suspended by their tail in an
environmental chamber and activity was recorded by a load
cell (Med Associates, St. Albans, VT). Measurements were
taken in 200-ms increments for 7 min, with threshold = 3
and gain = 8 (Supplementary Table 2). Because all mice
were uniformly active for the ﬁrst minute, immobility was
calculated by determining the percent of time spent
immobile during the last 6 min of the test. All animals that
climbed their tails during the TST were removed from
further behavioral and genotyping analyses and were not
included in the group sizes presented in Table 1.
To evaluate the role of Gabra3 on TST immobility,
male B6 and NZB mice received an intraperitoneal injec-
tion of vehicle, SB-205384 (2 or 4 mg/kg), or diazepam
(5 mg/kg), and were given the TST 30 min after injection.
SB-205384 (Tocris, Ellisville, MO) was dissolved in a mix
of sterile saline, 10% DMSO, and 25% Tween-80 imme-
diately before use. Diazepam was suspended at 5 mg/ml
in a saline solution containing 2.5% ethanol (Webster
Veterinary, Sterling, MA). Doses of both drugs were based
upon previously published behaviorally effective levels
(Cryan and Mombereau 2004; Navarro et al. 2006). One
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123week after TST testing, general activity and anxiety were
measured in the Open Field Test (OFT). Mice received the
same drug treatment as in the previous week and were
placed inside an open ﬁeld within a sound-attenuating
cubicle (Med Associates). Activity was recorded by infra-
red array for 10 min. General activity was measured by
total distance traveled (cm), and anxiety was measured by
the percent of time spent within the center 25% of the ﬁeld.
The effect of drug treatment on TST and OF behavior was
determined by using an unpaired, unequal variance t test
(JMP, SAS Software, Cary, NC).
Genotyping
DNA was obtained from a tail snip from each F2 mouse.
Genotyping was performed using the Sequenom platform
(Sequenom, San Diego, CA) as previously described (Pinto
et al. 2007). All DNA samples were genotyped in dupli-
cate. B6F2 offspring were genotyped for 350 SNPs, and
NZBF2 offspring were genotyped for 474 SNPs. SNP
locations were mapped to NCBI mouse genome build 37.1.
QTL analysis
The J/qtl and MapManager software packages were used
for QTL analysis. In J/qtl, a nonparametric one QTL scan
(EM model) was used to calculate a logarithm of odds
(LOD) score, and 1000 permutations were run to determine
the signiﬁcance threshold. In MapManager, each chromo-
some was evaluated by interval mapping, and 10,000
permutations were used to determine suggestive and sig-
niﬁcant likelihood ratio statistic (LRS) thresholds. Conﬁ-
dence intervals were calculated as ± 1 LOD (4.6 LRS).
Males and females were evaluated both separately and
together. In addition, each intercross was evaluated sepa-
rately and then SNP and phenotyping data for all F2 off-
spring were combined. For the combined data set, missing
genotype calls were inferred, yielding 828 informative
SNPs across the entire genome (approximately 1 SNP per
3 Mb). The combined data set was analyzed in both J/qtl
and MapManager, as described above. All marker pairs in
the combined data set were analyzed for epistatic effects
using the Interaction function of MapManager at p cutoff
value of 10
-5 (Supplementary Table 3). No interactions
were detected to be loci on different chromosomes that did
not involve the highly signiﬁcant QTLs on MMUX.
Gene expression analysis
Hippocampal tissue was collected from male B6, NZB, and
R3 mice (12 mice per strain). RNA was extracted by
phenol–chloroform phase separation and processed with an
RNAeasy miniprep kit (Qiagen, Valencia, CA). Samples
from four individuals per strain were pooled at equal
concentrations, and 5 lg from each pool was used as a
template to synthesize biotinylated cRNA (Affymetrix,
Santa Clara, CA). cRNA was hybridized to Affymetrix
GeneChip Mouse Genome 430 2.0 arrays. Data were nor-
malized with the GCRMA algorithm using the ArrayAssist
software package (Stratagene, La Jolla, CA). Any probe set
with an average intensity value of less than 100 was
considered below background level and removed from
subsequent analysis.
Real-time PCR (RT-PCR) was used to measure the
expression of candidate genes on MMUX. B6, NZB, and R3
hippocampal RNA pools (4 mice per pool) were created
using samples from different mice than those that were used
for microarray analysis. Two independent pools were gen-
erated for each strain and two technical replicates were run
on each pool. cDNA was ampliﬁed from each pool using a
Superscript III reverse transcription kit (Invitrogen). PCR
primers were designed to overlap exon–exon borders of
Gabra3, Gabra3, Gabrq, and Gpr50 (Supplementary
Table 1). RT-PCR was performed using a SYBR
 Green
mix (Bio-Rad, Hercules, CA) on an ABI 7900HT (Applied
Biosystems, Foster City, CA) and using Gapdh as a control.
RNA relative abundance was calculated using the delta-Ct
method. Statistical signiﬁcance was determined by t test
(GraphPad Prism, La Jolla, CA).
Sequencing
Genomic DNA from the parental strains was sequenced for
coding differences. Primers (Integrated DNA Technolo-
gies, Coralville, IA) were designed to cover the splice sites
and coding regions of all nine Gabra3 exons, and
Table 1 Summary of TST immobility for F0, F1, and F2 mice
Strain Sex Percent immobility SD n
C57BL/6J (B6) Male 63.9 0.16 11
C57BL/6J (B6) Female 64.2 0.10 9
NZB/BlNJ (NZB) Male 51.4 0.11 13
NZB/BlNJ (NZB) Female 50.1 – 2
RIIIS/J (R3) Male 5.3 0.09 14
RIIIS/J (R3) Female 21.4* 0.16 10
B6F1 Male 13.4 0.12 28
B6F1 Female 17.5 0.13 21
NZBF1 Male 8.1 0.05 21
NZBF1 Female 22.3* 0.12 16
B6F2 Male 15.3 0.15 142
B6F2 Female 22.4* 0.17 124
NZBF2 Male 18.7 0.17 160
NZBF2 Female 30.1* 0.22 118
* Signiﬁcantly different from other sex in strain/cross, p\0.001
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123sequencing was performed by the University of Chicago
DNA Sequencing Facility (Chicago, IL) using ﬂuorescent
dye termination. Sequences were assembled to the refer-
ence sequence NM_008067.
Results
Tail suspension of parental strains and F2 mice
Baseline TST immobility was determined for male and
female B6, NZB, and R3 inbred mouse strains (Table 1;
Fig. 1). B6 male and female mice exhibited similarly high
TST immobility. NZB males also exhibited high immo-
bility, but baseline TST immobility could be determined
for only two NZB females, as all others climbed their tails
during testing. In contrast to the B6 and NZB strains, R3
males exhibited extremely low immobility, while R3
female immobility was signiﬁcantly higher than that of R3
males, but still lower than NZB or B6 mice.
B6F2 and NZBF2 offspring were skewed toward the low
end of the immobility scale compared to the B6 and NZB
parental strains (Fig. 1, Supplementary Table 2). B6F2
mice ranged from 0 to 69% immobility (mean = 15%), but
almost 50% of the group was immobile for less than 10%
of the test time. NZBF2 mice exhibited an identical TST
immobility range (0–68%) compared to B6F2 mice but
averaged slightly higher immobility (19%). As with the
parental R3 strain, females from both crosses exhibited
signiﬁcantly higher TST immobility than males. The tail-
climbing behavior of the NZB females was not observed in
the female NZBF2 offspring at a greater frequency than in
females from the B6F2 cross.
QTL analysis
Interval mapping of data from all B6F2 mice identiﬁed a
locus on MMU6 that reached the genome-wide signiﬁcance
threshold of p\0.05 (Table 2, Figs. 2a, 3a). When only
data from male mice were analyzed, a SNP on MMU2
reached p\0.1 (Fig. 3b). In female B6F2 mice, a SNP on
MMU17 exceeded the threshold for suggestive linkage
(p\0.63) (Lander and Kruglyak 1995).
In the NZBF2 data set, a locus on MMUX exceeded the
signiﬁcance threshold for both J/qtl and MapManager
(p\0.05) (Figs. 2b, 3c). Both algorithms also identiﬁed
loci on MMU4, MMU13, and MMU17 that exceeded the
suggestive threshold. J/qtl analysis of the data from NZBF2
males alone identiﬁed a second suggestive locus on MMU4
and one on MMU18.
Combining the B6F2 and NZBF2 groups also produced
a signiﬁcant association with the MMUX locus (Fig. 2c)
Fig. 1 Frequency distribution of parental (F0) and F2 TST percent
immobility. TST immobility scores for each strain/cross were
separated into nine bins (1 = 0–9% immobility, 2 = 10–19%,
3 = 20–29%, 4 = 30–39%, 5 = 40–49%, 6 = 50–59%, 7 = 60–
69%, 8 = 70–79%, 9 = 80–89%) and plotted by frequency
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123and elevated the B6F2 MMU4 locus above the MapMan-
ager signiﬁcance threshold, although this locus was not
identiﬁed by J/qtl. J/qtl analysis identiﬁed a female-speciﬁc
QTL on MMUX with p = 0.13 (Fig. 3d).
RNA expression of QTL candidate genes
The hippocampus has been shown to play a key role in
depression and the response to antidepressants (Miller et al.
2008; Santarelli et al. 2003). Therefore, we analyzed hip-
pocampal expression of genes lying within the QTL con-
ﬁdence intervals for strain-speciﬁc differences. One gene
within the NZBF2-speciﬁc MMUX QTL, Gabra3 (GABAA
receptor a3 subunit), was expressed in both B6 and R3
hippocampus but was not expressed in NZB hippocampus
(probe set 1436957_at). RT-PCR was used to conﬁrm this
strain-speciﬁc expression difference and to measure the
expression of several adjacent candidate genes, including
Gabre, Gabrq, and Gpr50 (Fig. 4). As predicted by the
microarray data, Gabra3 expression was high in B6 and R3
mice but absent in NZB mice. Gabrq was expressed at
similar levels in all three strains, Gabre expression was not
detected in the hippocampus of any of the strains, and
Gpr50 expression was higher in B6 hippocampus than in
NZB or R3 hippocampus. The Gabra3 50 UTR, exons, and
intron/exon splice sites were sequenced in B6, NZB, and
R3 but no strain-speciﬁc SNPs were identiﬁed. The Gabra3
promoter region could not be sequenced due to a highly
repetitive structure (Mu and Burt 1999).
Effect of SB-205384 on TST and OFT behavior
NZB and B6 mice were treated with SB-205384, a GABAA
receptor a3 subunit agonist, or with diazepam, a nonspe-
ciﬁc GABAA receptor agonist (Meadows et al. 1998). At
the lower dose, SB-205384 signiﬁcantly (p\0.0001)
reduced TST immobility in B6 (n = 14) but not in NZB
(n = 9) mice compared to vehicle-treated mice (B6,
n = 12; NZB, n = 9) (Fig. 5a). The higher dose of
SB-205384 had no effect on TST immobility in either
strain. Diazepam signiﬁcantly (p\0.0001) increased TST
immobility in both B6 (n = 5) and NZB mice (n = 7).
In the OFT, neither dose of SB-205384 affected total
distance traveled in either B6 or NZB mice (Fig. 5b).
Diazepam signiﬁcantly increased distance traveled in B6
mice relative to controls (p = 0.03) and slightly, but not
signiﬁcantly, reduced distance traveled in NZB mice. In B6
mice, the higher dose of SB-205384 signiﬁcantly decreased
center time (p\0.01), while the lower dose had no effect
(Fig. 5c). Neither dose of SB-205384 affected NZB center
time. Diazepam signiﬁcantly decreased B6 center time but
signiﬁcantly increased NZB center time (p\0.01).
Discussion
In this study, two F2 hybrid crosses were used to identify
genetic loci underlying a behavioral despair phenotype in
mice. A B6-speciﬁc QTL on MMU6 and an NZB-speciﬁc
Table 2 Results from TST QTL analysis
Cross Data set Chr Position (Mb) Marker LOD Conﬁdence interval (Mb) Effect size (%) p value
B6F2 All 6 37,022,895 rs3678202 4.001 16.92–45.38 6.75 0.021
Male 2 57,512,265 rs3663027 3.777 38.38–102.72 11.67 0.064
Female 17 87,480,212 rs3689581 3.064 64.32–92.18 0.165
NZBF2 All X 69,924,084 rs13483821 5.795 48.07–70.16 9.15 0.001
13 7,998,546 rs6239339 2.948 0–14.84 0.250
4 99,636,849 rs13477868 2.888 82.45–118.85 0.272
17 27,716,601 rs4231402 2.875 0–52.80 0.277
Male 18 48,015,733 rs4139897 3.1 35.85–59.87 0.2
4 74,880,036 rs13477781 2.92 46.65–118.85 0.274
Combined All X 61,160,361 rs13483784 5.474 45.22–74.71 4.25 0.004
4 99,462,176 rs13477868 21.6
a (4.7) 93.80–110.87 4 0.0001
5 81,971,499 rs3658818 3.353 66.60–96.82 0.147
13 119, 532, 057 rs3708633 3.065 116.71–end 0.241
Male 2 61,738,719 rs4223189 3.44 47.35–92.85 0.175
13 7,998,546 rs6239339 3.27 6.09–14.54 0.236
Female X 5,278,656 rs13483708 4.923 0–9.78 1.4 0.013
13 119,532,057 rs3708633 3.45 116.79–end 0.17
a QTL derived from MapManager analysis, value represents LRS. An equivalent LOD score, calculcated using a 1 LOD = 4.6 LRS conversion
factor, is provided in parenthesis
Bold values represent genome-wide signiﬁcance (p\0.05)
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123QTL on MMUX were identiﬁed. Additional signiﬁcant loci
on MMU4 and MMUX were identiﬁed by combining
genotyping data from both crosses. Loci on MMU2,
MMU4, MMU5, MMU13, MMU17, and MMU18 excee-
ded the suggestive linkage threshold. Microarray expres-
sion data from the hippocampus of the parental strains were
used to identify the GABAA receptor a3 subunit gene,
Gabra3, as a strong candidate gene driving the NZB-spe-
ciﬁc MMUX association. In vivo pharmacological manip-
ulation of Gabra3 conﬁrmed a regulatory role for this gene
in mouse TST performance.
The selection of parental strains was informed by a large
inbred mouse strain survey of TST behavior. We hypothe-
sized that F2 intercrosses using parental strains representing
the high and low ends of the phenotypic spectrum might
yield signiﬁcant QTL results and that mapping efﬁciency
could be enhanced by maximizing the genetic difference in
the parental strains. Therefore, a low-immobility strain,
RIIIS/J, was crossed with two high-immobility strains,
C57BL/6J and NZB/BlNJ. The strains were derived from
three separate ancestral branches, allowing for greater
genetic diversity in the offspring (Beck et al. 2000). Inter-
estingly,TST behavior oftheF2offspringfrombothcrosses
was strongly skewed toward low immobility; more than half
of the B6F2 offspring exhibited less than 10% immobility
and more than half of the NZBF2 offspring exhibited less
than 20% immobility. In contrast, B6 9 C3H F2 hybrids
(Yoshikawa et al. 2002) and B6 9 DBA recombinant
inbred strains (Lad et al. 2007) exhibit a more even distri-
bution of TST immobility. The results presented here may
be explained by highly penetrant R3 alleles, particularly
those identiﬁed by mapping the combined cross.
QTL analysis identiﬁed several signiﬁcant loci, provid-
ing the ﬁrst replication of previously identiﬁed behavioral
despair QTLs. The B6F2 locus on MMU6, which accounts
for 7% of TST variability, mapped to a region within the
conﬁdence interval of a previously reported QTL identiﬁed
by two-locus interaction analysis of a B6 9 C3H (Table 3)
(Yoshikawa et al. 2002). To identify candidate genes,
whole-genome expression data was examined for genes
within this region that exhibited differential expression in
the hippocampus. Several genes within the conﬁdence
interval exhibited a more than twofold difference between
B6 and R3, including Copg2, a gene that lies within a
human autism QTL (Bonora et al. 2002), Ptn, which reg-
ulates catecholamine synthesis (Ezquerra et al. 2004), and
Fig. 2 Interval mapping for B6F2, NZBF2, and B6F2 ? NZBF2.
LOD scores generated by J/qtl identiﬁed a signiﬁcant (p\0.05) peak
on MMU6 in the B6F2 cross with an effect size of 7% (a), and a
signiﬁcant peak on MMUX in the NZBF2 cross with an effect size of
9% (b). Combining the genotyping data from both crosses narrowed
the size of the MMUX QTL (c)
b
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123Mkrn1, a ubiquitin ligase. A SNP database (http://cgd.jax.
org/ImputedSNPData/imputedSNPs.htm) was searched for
genes containing coding SNPs in B6 mice, and these SNPs
were examined in R3 and NZB mice (Szatkiewicz et al.
2008). Four genes, Cttnbp2, Rbm28, Olfr461, and Zfp398,
contained nonsynonymous coding changes; of these,
Cttnbp2 expression is restricted to brain areas relevant to
TST behavior, including the hippocampus and amygdala
(symatlas.gnf.org). Within the B6F2 male-speciﬁc MMU2
locus, the expression of Camk1d, which is activated by
calcium and calmodulin signaling, is fourfold higher in B6
hippocampus than in R3 hippocampus.
Analysis of the NZBF2 cross yielded a highly signiﬁcant
QTL on MMUX with an effect size of 9%. This region is
syntenic to the Xq28 region that has been associated with
affective disorders in multiple human populations (Baron
et al. 1987; Craddock et al. 2005). The MMUX locus has
been reported to interact with the MMU11 TST locus
identiﬁed by Yoshikawa et al. (2002), and both the MMUX
and MMU11 loci contain clusters of genes for GABAA
receptor subunits, as does an MMU5 TST QTL identiﬁed
by Liu et al. (2007) (Table 3).
The association of three different GABAA subunit gene
clusters with TST performance, derived from three separate
F2 crosses (NZB 9 R3, B6 9 C3H, and NMRI 9 129S6),
Fig. 3 Effect plots for signiﬁcant QTLs in the total B6F2 population
(a), B6F2 males (b), the total population of the combined cross (c),
and combined cross females (d). In general, homozygosity for the
RIIIS allele (RR) was associated with low TST immobility, while
heterozygosity (H) or homozygosity for the B6 (BB) or NZB (NN)
alleles was associated with higher TST immobility. One exception is
the MMU6 QTL in the total B6F2 population (A). Error bars = SEM
Fig. 4 Analysis of candidate
quantitative trait genes. LRS
scores generated by
MapManager indicated that the
NZBF2 MMUX QTL had a
conﬁdence interval of 21 Mb.
This region contains a cluster of
GABAA receptor subunit genes,
Gabre, Gabra3, and Gabrq,
along with another gene, Gpr50,
that has been suggested to be an
affective disorder QTL
candidate in humans. RT-PCR
analysis of these four genes in
hippocampal tissue from B6,
NZB, and R3 mice indicated
that expression of Gabra3 was
signiﬁcantly reduced in NZB
compared to B6 and R3. Gabre
was not expressed at a
detectable level. Error
bars = SEM. * p\0.05
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123strongly suggests a role for GABA signaling in the regu-
lation of behavioral despair. GABAA receptors are mem-
brane Cl
- channels composed of a, b, and c subunits.
Neuron-speciﬁc expression patterns have been determined
for ﬁve of the six known a subunits (Fritschy et al. 1992).
The a1 and a3 subunits are expressed most prominently in
the brain and exhibit differential staining patterns; notably,
the a3 subunit is preferentially expressed by serotonergic
neurons, which are the target of existing antidepressant
drug therapies (Gao et al. 1993). Gabra3 has also recently
been linked to the regulation of dopaminergic signaling
(Yee et al. 2005a, b), and a polymorphism in GABRA3 has
been associated with bipolar disorder (Massat et al. 2002).
We compared expression of the MMUX GABAA
receptor subunit genes Gabra3, Gabre, and Gabrq,i n
hippocampal tissue from the NZB, B6, and R3 strains.
Expression of an adjacent gene, Gpr50, was also examined
because it has been associated with bipolar disorder in
humans (Thomson et al. 2005). A strong candidate gene
would be expected to exhibit similar levels of expression in
B6 and R3 mice, as this QTL was not detected in the B6F2
cross, but have different expression levels between NZB
mice and the B6 and R3 strains; of the genes examined,
only Gabra3 met these criteria.
Considering the strain-speciﬁc differences in Gabra3
expression and the role that the a3 subunit plays in
monoaminergic signaling, we hypothesized that this gene
was responsible for the MMUX linkage association iden-
tiﬁed in the NZBF2 cross. To test this hypothesis, we
evaluated the effect of SB-205384, a GABAA receptor
agonist selective for a3-containing GABAA receptors, on
TST behavior in B6 and NZB mice. If the a3 subunit
regulates TST performance, B6 mice, which express
Gabra3, would be expected to respond to the drug, while
NZB mice, which lack Gabra3 expression, would not
respond. Diazepam, a non-speciﬁc GABAA receptor ago-
nist, was used as a control to measure the general function
of GABAA receptors in NZB mice.
In B6 mice, a low dose of SB-205384 decreased TST
immobility without affecting either general locomotor
activity or OFT center preference. The magnitude of the
effect of 2 mg/kg SB-205384 on reducing TST immobility
in B6 mice was similar to the effect of chronic ﬂuoxetine
treatment (Miller et al., unpublished data), indicating that
this dose of SB-205384 is an effective antidepressant
treatment. At a higher dose, SB-205384 lost its effect on
TST behavior but had the same effect on OFT center
preference as diazepam. The dose-dependent efﬁcacy of
SB-205384 on TST immobility and OFT center preference
is likely explained by the pharmacology of the drug:
SB-205384 affects decay time and magnitude of the
GABA-activated current for many a subunit combinations
but has a tenfold greater speciﬁcity for the a3 subunit
compared to other a subunits (Meadows et al. 1998).
Therefore, the lower dose of SB-205384 is likely to act
solely on the a3 subunit. Although the higher dose of
SB-205384 is still selective for the a3 subunit, it is also
able to activate receptors containing other a subunits,
similar to the effects of diazepam.
In contrast to B6 mice, NZB mice showed no behavioral
response in either the TST or the OFT to any dose of
SB-205384, supporting a speciﬁc role for the a3 subunit in
Fig. 5 Effect of GABRA3 agonist SB-205384 and GABAA agonist
diazepam on TST and OFT behavior. a SB-205384 (2 mg/kg)
signiﬁcantly reduced TST immobility in B6 but not in NZB mice.
Diazepam signiﬁcantly increased TST immobility in both strains.
b SB-205384 had no effect on distance traveled by either strain in the
open ﬁeld. Diazepam signiﬁcantly increased distance traveled by B6
but not by NZB mice. c SB-205384 (4 mg/kg) signiﬁcantly decreased
center time in the open ﬁeld in B6 mice; diazepam signiﬁcantly
decreased percent of time spent in the center of the ﬁeld by B6 mice
and increased the amount of time spent in the center of the ﬁeld by
NZB mice. Error bars = SEM. * p\0.03; ** p\0.001
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123regulating TST performance. Treatment with the non-
speciﬁc GABAA agonist diazepam affected TST and OFT
performance in both strains, indicating that NZB mice are
capable of responding to GABAergic drugs acting at sub-
units other than a3. The diazepam dose did contain a
negligible (2.5%) amount of ethanol required to solubilize
the drug that was not present in the vehicle control and
SB-205384 treatment. It is possible this impacted the
behavioral testing independent of the diazepam, although
this is unlikely.
We resequenced the Gabra3 50 UTR, coding regions,
and intron/exon splice sites in the three parental strains in
order to identify structural variants that might cause the
loss of Gabra3 expression in NZB hippocampus. We found
no sequence variations among the three strains. However,
the mouse Gabra3 promoter contains a region of 55 GA
repeats that have been shown to have an enhancer function
in Gabra3 expression (Mu and Burt 1999). As deletion of
these GA repeats results in a signiﬁcant reduction in
Gabra3 expression in vitro, it is possible that NZB mice
carry a mutation that disrupts the promoter region.
Unfortunately, attempts to resequence across this region in
the parental strains were unsuccessful.
Gabra3 has been previously knocked out in mice and
the resulting animals have been shown to exhibit low
immobility in the Forced Swim Test, another test of
behavior despair (Fiorelli et al. 2008). Although this does
appear to stand in contrast to the data generated with
SB-205384 in which increased activity of GABRA3 led to
decreased immobility, the knockdown does provide further
evidence that modulation of GABRA3 activity directly
impacts behavioral despair. The knockout data also further
underscores the genetic complexity of the behavioral
despair phenotype. The knockout was phenotyped on a
C57BL/6J 9 129X1/SvJ hybrid background. It is likely
that this unique genetic background impacted the pheno-
typic expression of the knockout, just as the B6 and R3
mice in this study had divergent TST proﬁles despite
expressing similar levels of Gabra3. In this sense, the
difference between the three strains tested in the present
experiments can be considered a good model of the
genetics of human psychiatric disorders. Recent genome-
wide association studies indicate that the majority of psy-
chiatric disorders are caused by a large number of small
effect-size genes acting in a unique combination in each
individual (Purcell et al. 2009; Stefansson et al. 2009).
The independent identiﬁcation of Gabra3 as a candidate
QTL in the present study suggests that this gene may be a
viable target for antidepressant therapy. Although current
antidepressant therapies focus on the monoaminergic
Table 3 Summary of published genome-wide signiﬁcant TST QTLs from F2 and RI crosses
Chr Position SNP ID Cross Group
2 55,229,057 rs6201706 B6 9 RIIIS (males) Miller 2010
3 34 cM NA DeFries high/low activity Turri 2001
4 78,698,065 rs13477796 BXD recombinant inbred (B6 9 DBA) Lad 2007
4 99,462,176 rs13477868 (B6 9 RIIIS) ? (NZB 9 RIIIS) Miller 2010
4 128,974,322 D4mit203 B6 9 C3H Yoshikawa 2002
4 132,599,443 D4mit204 NMRI 9 129S6 Lui 2006
5 14 cM NA DeFries high/low activity Turri 2001
5 73,166,580 D5mit134 CS strain (NBC 9 SII) Tomida 2009
5 104,491,174 D5mit41 NMRI 9 129S6 Lui 2006
6 37,003,047 rs3678202 B6 9 RIIIS Miller 2010
6 53,125,925 D6mit183 B6 9 C3H Yoshikawa 2002
8 104,548,706 D8mit242 B6 9 C3H Yoshikawa 2002
11 45,561,177 D11mit271 B6 9 C3H Yoshikawa 2002
11 50 cM NA DeFries high/low activity Turri 2001
12 83,437,864 D12mit158 NMRI 9 129S6 Lui 2006
13 7,998,546 rs6239339 (B6 9 RIIIS) ? (NZB 9 RIIIS) Miller 2010
14 50,072,764 D14mit257 B6 9 C3H Yoshikawa 2002
15 3,229,130 rs13459176 BXD recombinant inbred (B6 9 DBA) Lad 2007
18 72,045,787 D18mit186 NMRI 9 129S6 Lui 2006
19 40 cM NA DeFries high/low activity Turri 2001
X 4,876,764 rs13483708 (B6 9 RIIIS) ? (NZB 9 RIIIS) (females) Miller 2010
X 60,167,851 rs13483784 NZB 9 RIIIS Miller 2010
X 118,100,412 DXmit172 B6 9 C3H Yoshikawa 2002
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123signaling system, several lines of evidence suggest a role
for GABA signaling in depression. In addition to the
linkage of the GABRA3-containing Xq28 region to affec-
tive disorders, the a1 and a5 subunits have also been
associated with affective disorders in linkage studies (Oruc
et al. 1997; Papadimitriou et al. 1998). Depressed patients
have been shown to have reduced cortical, cerebrospinal
ﬂuid (CSF), and plasma GABA levels, and treatment with
either antidepressants or electroconvulsive therapy (ECT)
increases cortical GABA concentrations and GABA
receptor density (Sanacora et al. 1999, 2002; Tunnicliff and
Malatynska 2003). In animal models of depression, several
GABAA agonists have been shown to reduce putative
depressive symptoms, and deletion of Gad65, which reg-
ulates GABA synthesis, affects multiple depression-like
behaviors (Cryan et al. 2005; Stork et al. 2000; Tunnicliff
et al. 1973). There may be a reciprocal role between the
monoaminergic and GABAergic systems, as deletion of the
5HT1A receptor reduces GABA signaling in the hippo-
campus, while antidepressant treatment increases GAB-
Aergic signaling (Brambilla et al. 2003).
This work clearly demonstrates that F2 mapping can be
combined with whole-genome gene expression analysis to
successfully identify genetic determinants of complex
behaviors. In addition to providing independent conﬁrma-
tion of previously published TST QTLs on MMU4 and
MMU6 and generating several new signiﬁcant genetic
associations, we identiﬁed Gabra3 as a novel candidate
gene and conﬁrmed the regulatory role of Gabra3 on TST
performance using in vivo pharmacological manipulation.
As Gabra3 is preferentially expressed by monoaminergic
neurons, it may represent a prime therapeutic target in the
treatment of depression.
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